CALCIUM CITRATE ANHYDROUS

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C6H5O7.3Ca
Molecular Weight	498.433
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=FNAQSUUGMSOBHW-UHFFFAOYSA-H

InChI=1S/2C6H8O7.3Ca/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Hypocalcemia 75 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 504	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 428	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 428	Unknown Approved Use Unknown
Unknown 2578
Hypocalcemia 75 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8429	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors.	1999 Feb 26	10026162
[Early stage of cardiomyopathy: mechanisms of damage and compensation].	1999 Jul	10643616
Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension?	1999 Jul 30	10419463
Characterization of the human cysteinyl leukotriene CysLT1 receptor.	1999 Jun 24	10391245
Aluminum is a weak agonist for the calcium-sensing receptor.	1999 May	10231437
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.	1999 Sep 20	10509933
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.	2000 Aug	10970766
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density.	2000 Aug	10913914
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.	2000 Dec	11093801
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V.	2000 Feb 11	10660602
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.	2000 Feb 15	10660688
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.	2000 Jan 15	10623810
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.	2000 Jan 7	10617657
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.	2000 Jul 17	10899114
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.	2000 Jun	10963052
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway.	2000 May	10780946
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.	2000 Nov	11089548
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.	2000 Nov	11040061
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.	2000 Oct 15	11054866
ATP induces dephosphorylation of myosin light chain in endothelial cells.	2000 Sep	10942722
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.	2000 Sep	10936204
Characterization of the human cysteinyl leukotriene 2 receptor.	2000 Sep 29	10851239
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.	2001 Apr 7	11298490
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.	2001 Aug 28	11513607
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.	2001 Jul	11435522
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.	2001 Jun	11425647
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.	2001 Mar 15	11238657
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.	2001 Mar 2	11230109
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.	2001 Nov	11701772
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.	2001 Nov 1	11705452
Familial intrahepatic cholestasis 1: studies of localization and function.	2001 Oct	11584374
Microarray analysis of differential gene expression in lead-exposed astrocytes.	2001 Oct 1	11578147
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.	2001 Sep	11500311
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.	2001 Sep 15	11535132
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.	2002	12421626
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.	2002 Jul	12101159
Human kidney diamine oxidase: heterologous expression, purification, and characterization.	2002 Jun	12072962
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.	2002 May 15	11988098
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.	2002 Sep 15	12069687
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.	2003 Jan	12388232
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.	2006 Oct 20	16960820
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.	2014 Jul	24705069

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

CALCIUM CITRATE ANHYDROUS

Common Name

English

1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, CALCIUM SALT (2:3)

Common Name

English

Calcium citrate [WHO-DD]

Common Name

English

CALCIUM CITRATE [HSDB]

Common Name

English

INS NO.333(III)

Code

English

TRICALCIUM CITRATE

Systematic Name

English

CALCIUM CITRATE [MI]

Common Name

English

INS-333(III)

Code

English

E-333(III)

Code

English

Classification Tree Code System Code

CODEX ALIMENTARIUS (GSFA)

INS-333(III)